Science Corporation, the neural engineering and brain-computer interface company, today announced the appointment of its Chief Strategy Officer, Darius Shahida, as President, effective immediately. Shahida will continue in his responsibilities leading the company’s work with investors, global commercialization, and partnership efforts and will continue to report to the CEO and co-founder, Max Hodak.

“In many ways, our company is entering a new commercial era. Darius can and will be a force multiplier around these efforts, as we begin to translate years of important scientific and technical work into products that can change health outcomes and powerfully impact the lives of our patients,” said Hodak. “Darius is already helping us build the commercial organization and operating infrastructure required for this next phase.”

“I’m honored by the trust Max has placed in me,” said Shahida. “His vision has already established Science as a leader in the field, including bringing the first commercially available brain-computer interface for form vision restoration to patients. I’m excited by the work that remains ahead of us. I believe the team we are building and the work we are doing have the potential to improve the lives of millions of people around the world. I feel incredibly fortunate to play a part in making this vision a reality.”

Science recently announced the commercial launch in Europe and the United Kingdom of PRIMA, its retinal implant for blindness caused by geographic atrophy in patients with macular degeneration. PRIMA received CE marking in July and is being commercially prescribed and implanted by doctors for the appropriate patient. It is the first BCI approved for form vision restoration anywhere in the world.

About Science Corporation

Science Corporation is a vertically integrated, full-stack neural engineering company. Our mission is to restore and extend life by transcending the limits of biology. Our first commercially available product is the PRIMA implant for blindness caused by geographic atrophy in patients with age-related macular degeneration. We are developing other advanced brain-computer interface technologies and devices to address critical unmet medical needs and, longer term, to transform the human condition through neural engineering and advanced perfusion technology. Science is headquartered in Alameda, California, with offices in Paris, France. For more information, please visit: www.science.xyz.

Media gallery

About The Author
Business Wire